Antihyperlipidemic Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2023-28 - PowerPoint PPT Presentation

About This Presentation

Antihyperlipidemic Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2023-28


According to the latest research report by IMARC Group, The global antihyperlipidemic drugs market size reached US$ 12.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.0 Billion by 2028, exhibiting a growth rate (CAGR) of 4.6% during 2023-2028. More Info:- – PowerPoint PPT presentation

Number of Views:0
Slides: 13
Provided by: MarcelMikaelson


Transcript and Presenter's Notes

Title: Antihyperlipidemic Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2023-28

Global Antihyperlipidemic Drugs Market Research
and Forecast Report 2023-2028
  • Format PDFEXCEL

2023 IMARC All Rights Reserved
About IMARC Group
  • International Market Analysis Research and
    Consulting Group is a leading adviser on
    management strategy and market research
    worldwide. We partner with clients in all regions
    and industry verticals to identify their
    highest-value opportunities, address their most
    critical challenges, and transform their
  • IMARCs information products include major
    market, scientific, economic and technological
    developments for business leaders in
    pharmaceutical, industrial, and high technology
    organizations. Market forecasts and industry
    analysis for biotechnology, advanced materials,
    chemicals, food and beverage, travel and tourism,
    nanotechnology and novel processing methods are
    at the top of the companys expertise.
  • IMARCs tailored approach combines unfathomable
    insight into the dynamics of companies and
    markets with close cooperation at all levels of
    the client organization. This ensures that our
    clients achieve unmatchable competitive
    advantage, build more proficient organizations,
    and secure lasting results.

Report Highlight and Description
  • According to the latest report by IMARC Group,
    titled "Antihyperlipidemic Drugs Market Global
    Industry Trends, Share, Size, Growth, Opportunity
    and Forecast 2023-2028," the global
    antihyperlipidemic drugs market size reached US
    12.0 Billion in 2022.
  • Antihyperlipidemic drugs help in lowering blood
    lipid levels, including cholesterol. These
    medications are also known as hypolipidemic or
    lipid-lowering drugs in reference to their main
    physiological effects. They can be taken along
    with different medicines to lower cholesterol and
    reduce the risk of developing certain diseases.
    Some commonly available antihyperlipidemic drugs
    include cholesterol absorption inhibitors, fibric
    acid derivatives, statins, antihyperlipidemic
    combinations, bile acid sequestrants, and PCSK9
  • These drugs can prevent absorption, facilitate
    the elimination of more lipids in feces, and
    increase good cholesterol levels to lower bad
    cholesterol. At present, antihyperlipidemic drugs
    are available in different classes across the
    globe, which can be given depending on the
    patients underlying disease, cholesterol
    profile, and other factors.
  • Request for a PDF sample of this report

Report Description
  • Global Antihyperlipidemic Drugs Market Trends
  • The rising prevalence of hyperlipidemia due to
    the high consumption of fatty foods and nicotine
    addiction represents the primary factor driving
    the market growth. Moreover, hyperlipidemia
    increases the risk of developing coronary artery
    disease (CAD), which is a leading cause of death
    among adults. In line with this, the escalating
    demand for antihyperlipidemic drugs to improve
    the low levels of high-density lipoprotein (HDL)
    cholesterol while reducing the high levels of
    low-density lipoprotein (LDL) cholesterol and
    triglycerides are positively influencing the
    market growth. Additionally, antihyperlipidemic
    drugs are used to treat high cholesterol levels
    and various lipid disorders in children.
  • Along with this, the rising product demand to
    reduce hospitalization rates and premature deaths
    due to the increase in the number of genetic and
    acquired disorders of lipid and lipoprotein
    metabolism among the pediatric population has
    catalyzed market growth. Furthermore, several key
    players are developing, synthesizing, and
    evaluating a variety of new molecules for these
    drugs, thereby contributing to market growth.
    Other factors, including the rising prevalence of
    sedentary lifestyles, increasing incidences of
    cardiovascular disorders, surging approval of new
    and advanced drugs, and expanding geriatric
    population, are also anticipated to create a
    positive market outlook.
  • Looking forward, IMARC Group expects the market
    value to reach US 16.0 Billion by 2028,
    expanding at a CAGR of 4.6 during 2023-2028.
  • View Report TOC, Figures and Tables

Report Segmentation
  • Breakup by Drug Class
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
  • Breakup by Route of Administration
  • Oral
  • Intravenous
  • Breakup by Distribution Channel
  • Hospital Pharmacies

Report Segmentation
  • Retail Stores
  • Online Retailers
  • Breakup by Region
  • North America
  • Asia-Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Competitive Landscape with Key Players
  • Amgen Inc.
  • AstraZeneca plc
  • Daiichi Sankyo Company Limited
  • Merck Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Key Questions Answered in the Report
Table of Contents
  • 1    Preface2    Scope and Methodology    2.1  
     Objectives of the Study    2.2  
     Stakeholders    2.3    Data Sources       
    2.3.1    Primary Sources        2.3.2  
     Secondary Sources    2.4    Market Estimation 
          2.4.1    Bottom-Up Approach        2.4.2  
     Top-Down Approach    2.5    Forecasting
    Methodology3    Executive Summary4  
     Introduction    4.1    Overview    4.2    Key
    Industry Trends5    Global Antihyperlipidemic
    Drugs Market    5.1    Market Overview    5.2  
     Market Performance    5.3    Impact of
    COVID-19  5.4    Market Forecast
  • 6     Market Breakup by Drug Class
  • 6.1 Statins
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast       

Table of Contents
  • 6.4 Fibric Acid Derivatives
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
  • 6.6 Combination
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
  • 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
  • 7 Market Breakup by Route of Administration
  • 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
  • 7.2 Intravenous
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

  • 2023 IMARC All Rights Reserved
  • This Publication and all its contents unless
    otherwise mentioned are copyrighted in the name
    of International Market Analysis Research and
    Consulting (IMARC). No part of this publication
    may be reproduced, repackaged, redistributed or
    resold in whole or in any part. The publication
    may also not be used in any form or by and means
    graphic electronic or mechanical, including
    photocopying, recording, taping or by information
    storage or retrieval, or by any other form,
    without the express consent of International
    Market Analysis Research and Consulting (IMARC).
  • Disclaimer All contents and data of this
    publication, including forecasts, data analysis
    and opinion have been based on information and
    sources believed to be accurate and reliable at
    the time of publishing. International Market
    Analysis Research and Consulting makes no
    representation of warranty of any kind as to the
    accuracy or completeness of any Information
    provided. IMARC accepts no liability whatsoever
    for any loss or damage resulting from opinion,
    errors or inaccuracies if any found this
  • IMARC, IMARC Group and Global Therapy Insight
    Series are registered trademarks of International
    Market Analysis Research and Consulting. All
    other trademarks used in this publication are
    registered trademarks of their respective

Contact Us
Visit us at
TELEPHONE 1-631-791-1145 E-MAIL
Write a Comment
User Comments (0)